ecrin-mdr-crcClinical2021IPD Sharing (as of September 2021): Yes Description: The sponsor’s representatives (e.g. monitors, auditors) and/or regulatory authorities will be allowed access to source data for source data verification in which case a review of those parts of the hospital records relevant to the study may be required. Time frame: The data of the study will be kept 15 years after the end of the study according Norwegian law. Access Criteria: Access to the data has to be approved by the PI. Additional information available: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, Analytic CodeNeoplasm MetastasisColo-rectal CancerPeritoneal MetastasesNeoplasm MetastasisColo-rectal CancerPeritoneal MetastasesInterventionalhttps://newmdr.ecrin.org/Study/2390571Norway9NIPEC-LTOxaliplatinHIPECCRSECRIN MDRRecruitingfalseNormothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)Feasibility study regarding 20 Patients with peritoneal metastases from colorectal cancer treated with cytoreductive surgery and HIPEC and subsequently with 4 courses of normothermic intraperitoneal chemotherapy - long term (NIPEC-OXA) with oxaliplatin.2021-09-152390571NCT05056389